Lu AF28996 in Patients With Parkinson's Disease

2023-507785-12-00 Protocol 18252A Human pharmacology (Phase I) - Other Ended

Start 22 Jul 2024 · End 12 Feb 2026 · Status Ended · 3 EU/EEA countries · 5 sites · Protocol 18252A

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 80
Countries 3
Sites 5

Parkinson's Disease

Key facts

Sponsor
H. Lundbeck A/S
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
22 Jul 2024 → 12 Feb 2026
Decision date (initial)
2024-06-03
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-507785-12-00
ClinicalTrials.gov
NCT04291859

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Parkinson's Disease

VersionLevelCodeTermSystem organ class
20.0 PT 10061536 Parkinson's disease 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

H. Lundbeck A/S

Sponsor organisation
H. Lundbeck A/S
Address
Ottiliavej 9
City
Valby
Postcode
2500
Country
Denmark

Scientific contact point

Organisation
H. Lundbeck A/S
Contact name
H. Lundbeck A/S

Public contact point

Organisation
H. Lundbeck A/S
Contact name
H. Lundbeck A/S

Locations

3 EU/EEA countries · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 4 1
Germany Ended 20 1
Spain Ended 30 3
Rest of world
United States
26

Investigational sites

France

1 site · Ended
Centre Hospitalier Universitaire De Caen Normandie
Neurology, Avenue De La Cote De Nacre, Cs 30001, Caen Cedex 9

Germany

1 site · Ended
curiositas ad sanum Studien und Beratungs GmbH
NA, Alpenstrasse 9, 85560, Ebersberg

Spain

3 sites · Ended
University Hospital Virgen Del Rocio S.L.
Neurology, Avenida De Manuel Siurot S/n, 41013, Sevilla
Hospital Universitari General De Catalunya
Neurology, Carrer Pedro I Pons 1, 08195, Sant Cugat Del Valles
Hospital Universitari Vall D Hebron
Neurology, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2025-01-17 2026-01-05 2025-07-31 2025-09-10
Germany 2024-07-22 2026-02-12 2024-08-19 2025-09-10
Spain 2024-08-08 2026-01-28 2024-10-02 2025-09-10

Application history

11 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-14 Germany Acceptable with conditions
2024-05-23
2024-05-24
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-06-26 Germany Acceptable with conditions
2024-05-23
2024-06-26
3 NON SUBSTANTIAL MODIFICATION NSM-2 2024-07-24 Germany Acceptable with conditions
2024-05-23
2024-07-24
4 SUBSTANTIAL MODIFICATION SM-2 2024-10-04 Germany Acceptable
2025-01-13
2025-01-13
5 NON SUBSTANTIAL MODIFICATION NSM-3 2025-03-18 Acceptable
2025-01-13
2025-03-18
6 SUBSTANTIAL MODIFICATION SM-3 2025-03-20 Germany Acceptable 2025-04-09
7 SUBSTANTIAL MODIFICATION SM-4 2025-03-20 Acceptable 2025-04-15
8 NON SUBSTANTIAL MODIFICATION NSM-4 2025-05-16 Acceptable 2025-05-16
9 NON SUBSTANTIAL MODIFICATION NSM-5 2025-07-04 Germany Acceptable 2025-07-04
10 SUBSTANTIAL MODIFICATION SM-5 2025-09-15 Germany Acceptable 2025-10-01
11 NON SUBSTANTIAL MODIFICATION NSM-6 2025-10-21 Germany Acceptable 2025-10-21